Margarida Azevedo, MSc,  —

Tau and FUS proteins may contribute to a cellular process common to both amyotrophic lateral sclerosis (ALS) and dementia, a rare case suggests. The case was reported in a study, “Combined FUS+ Basophilic Inclusion Body Disease and Atypical Tauopathy Presenting with an ALS/MND‐plus Phenotype,” published…

ProMIS Neurosciences announced that it is moving toward selecting antibodies — from the many identified in earlier work — that specifically target the toxic proteins that accumulate in the brains of amyotrophic lateral sclerosis (ALS) and Alzheimer’s patients, and that may work as therapies. Specifically for ALS, the identified antibodies target TDP43…

A gene therapy that might treat familial amyotrophic lateral sclerosis (ALS), an inherited form of the disease, was recently granted orphan drug status by the European Medicines Agency (EMA), an award that carries incentives to promote potential treatments for rare diseases. The investigative therapy is in preclinical development…

Clinigen Group recently partnered with Mitsubishi Tanabe Pharma Corporation to launch an early access program in Europe for Radicava (edaravone), an intravenous treatment for amyotrophic lateral sclerosis (ALS). The therapy is not yet approved in Europe, but the early access program will help make it available…

The Muscular Dsytrophy Association (MDA) awarded 13 new grants totaling $2.6 million to find treatments for neuromuscular disorders, including amyotrophic lateral sclerosis (ALS). The 13 grants are divided into three types: Five grants were awarded to recognized, independent researchers; Five development grants were awarded to early-career scholars, and;…

The Muscular Dystrophy Association (MDA) recently awarded the Massachusetts General Hospital (MGH) a $750,000 human clinical trial grant to study positron emission tomography (PET) imaging to measure inflammation in amyotrophic lateral sclerosis (ALS) patients as a potential biomarker. This grant, which is part of a nonprofit partnership called…

The ALS Association and Cytokinetics will continue to collaborate in the fight against amyotrophic lateral sclerosis (ALS) through a series of initiatives and research efforts, the organizations recently announced. As part of this partnership, biopharmaceutical company Cytokinetics is renewing its sponsorship of nationally recognized ALS Association events, including the National…

A new Japanese joint venture company called MAGiQ Therapeutics — the result of a collaboration between Q Therapeutics and Reprocell — aims to develop cell and gene therapies for demyelinating and degenerative diseases of the central nervous system. Among the first diseases its efforts will target is amyotrophic lateral sclerosis (ALS), a…

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on the conditional marketing authorization of masitinib for the treatment of amyotrophic lateral sclerosis (ALS), the therapy’s maker, AB Science, recently announced in a press release. Masitinib is a tyrosine kinase inhibitor (TKI) being developed by AB Science to treat symptoms of…

Health Canada accepted Mitsubishi Tanabe Pharma’s new drug submission (NDS) for edaravone as an intravenous treatment option for amyotrophic lateral sclerosis (ALS). Edaravone is currently approved as a treatment for ALS in Japan, South Korea, and the United States (where it is marketed by Mitsubishi Tanabe as Radicava).